BioSight
Companies
ARVINAS, INC. logo

ARVN

NASDAQNEW HAVEN, CT
ARVINAS, INC.

Arvinas develops PROTAC protein degraders, a drug modality designed to destroy disease-causing proteins inside cells rather than simply blocking their function like traditional small molecule drugs. The company has multiple candidates in clinical development across oncology and other therapeutic areas, including vepdegestrant (in late-stage trials), ARV-102, ARV-806, ARV-393, and ARV-027, along with earlier-stage programs targeting difficult-to-drug protein targets like pan-KRAS.

Price history not yet available for ARVN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar